Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050291 · ClinicalTrials.gov registry record · Phase 1
Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
A Phase 1 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06050291 is a Phase 1 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 28 participants.
The verdict
NCT06050291, a Phase 1 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions.
Interventions
- DRUG Fixed-Dose Combination (FDC) Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-01-20 |
| Est. Completion | 2024-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06050291
The ClinicalTrials.gov registry entry for NCT06050291 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fixed-Dose Combination (FDC) Tablet is the first listed.
NCT06050291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06050291 about?
NCT06050291 is a clinical study titled "Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe". This study will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions.
What is the current status of trial NCT06050291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-01-20. Estimated completion is 2024-04-07.
What interventions are being tested in trial NCT06050291?
The interventions under investigation include: Fixed-Dose Combination (FDC) Tablet (DRUG).
Who is sponsoring clinical trial NCT06050291?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.